Emmaus Life Sciences Inc. announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration voted 10-to-3 that the overall Benefit-Risk profile of Endari for the treatment of sickle cell disease (SCD) is favorable. The FDA has set a PDUFA target action date for July 7, 2017.

Novartis exercised its option to acquire Selexys Pharmaceuticals based on the SUSTAIN Phase II clinical trial of SelG1, an anti-P-selectin antibody.

Scientists at Stanford University School of Medicine have used the CRISPR gene-editing tool to repair the gene that causes sickle cell disease in stem cells.

Swiss drugmaker Novartis will invest up to an extra $15 million in Gamida Cell, an Israeli developer of stem cell therapies, Gamida said on Sunday.   Novartis last year invested $35 million in the company for a 15 percent stake, in a deal that could reach $600 million if Novartis exercises a buyout option that […]